SPIN-LABELED ARABINOGALACTAN AS MRI CONTRAST AGENT

被引:38
作者
GALLEZ, B [1 ]
LACOUR, V [1 ]
DEMEURE, R [1 ]
DEBUYST, R [1 ]
DEJEHET, F [1 ]
DEKEYSER, JL [1 ]
DUMONT, P [1 ]
机构
[1] UNIV CATHOLIQUE LOUVAIN,DEPT PHARMACEUT SCI,MED CHEM LAB,B-1200 BRUSSELS,BELGIUM
关键词
NITROXYL; ASIALOGLYCOPROTEIN; MAGNETIC RESONANCE IMAGING; LIVER; CONTRAST AGENT;
D O I
10.1016/0730-725X(94)92353-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In this study, we report the synthesis and the evaluation as MRI contrast agent of arabinogalactan/pyrrolidinoxyl radicals (PCA) covalent adduct (SLAG: Spin Labelled ArabinoGalactan). Arabinogalactan was used as targeting device, as it is recognized by the asialoglycoprotein receptor specific to the hepatocytes. The higher relaxivity R(1) in water of SLAG, compared with small hydrophilic nitroxyl radicals, was explained by the molecular dynamics study using EPR spectroscopy that showed some immobilization of the radical into the polysaccharide. A binding study on isolated hepatocytes revealed that SLAG still recognizes the asialoglycoprotein receptor. MR imaging was performed using spin-echo T-1 weighted images on mice to compare the contrast effect obtained with SLAG and PCA after TV injection (1 mmol/kg free radical). The percent signal enhancement observed in the liver 5 min after IV injection was 40 +/- 3% and 13 +/- 5% for SLAG and PCA, respectively. The signal was also dramatically increased in the renal cortex. This latter effect as well as the prolonged duration of the contrast (+/-3 h), indicates at least a partial nonselective biodistribution; the high concentration needed to obtain a contrast effect could account for the saturation of the asialoglycoprotein receptor and hence for the apparent nonselective biodistribution.
引用
收藏
页码:61 / 69
页数:9
相关论文
共 38 条
[1]  
Berliner, Spin labeling, Theory and Applications, (1976)
[2]  
Swartz, Use of nitroxides to measure redox metabolism in cells and tissues, J. Chem. Soc. Faraday Trans., 83, pp. 191-202, (1987)
[3]  
Swartz, Metabolically responsive contrast agents, Advances in Magnetic Resonance Imaging, pp. 49-71, (1989)
[4]  
Swartz, Glockner, Measurements of the concentration of oxygen in biological systems using EPR techniques, Advanced EPR in Biology and Biochemistry, pp. 753-782, (1989)
[5]  
Swartz, Glockner, Measurement of oxygen by EPRI and EPRS, EPR Imaging and In Vivo EPR, pp. 261-290, (1991)
[6]  
Brasch, Work in progress: Methods of contrast enhancement for NMR imaging and potential applications, Radiology, 147, pp. 781-788, (1983)
[7]  
Brasch, London, Wesbey, Tozer, Nitecki, Williams, Doemeny, Tuck, Lallemand, Work in progress: Nuclear magnetic resonance study of a paramagnetic nitroxide contrast agent enhancement of renal structures in experimental animals, Radiology, 147, pp. 773-779, (1983)
[8]  
Ehman, Wesbey, Moon, Williams, Mc Namara, Couet, Tozer, Brasch, Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent, Magn. Reson. Imaging, 3, pp. 89-97, (1985)
[9]  
McNamara, Wesbey, Brasch, Sievers, Lipton, Higgins, Magnetic resonance of acute myocardial infarction using a nitroxyl spin label (PCA), Invest. Radiol., 20, pp. 591-595, (1985)
[10]  
Grodd, Paajanen, Eriksson, Revel, Terrier, Brasch, Comparison of ionic and nonionic spin labels for urographic enhancement in magnetic resonance imaging, Acta Radiol., 28, pp. 593-600, (1987)